EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cadherin-17 as a target for the immunoPET of adenocarcinoma

Samantha Delaney, Outi Keinänen, Dennis Lam, Andrew L Wolfe, Takao Hamakubo, Brian M Zeglis iD

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06709-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Samantha Delaney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, NY, 10021, USA. Hauptthemen laut MEDLINE: Zirconium, Cadherins, Radioisotopes. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for the National Institutes of Health, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Cadherin-17 (CDH17) is a calcium-dependent cell adhesion protein that is overexpressed in several adenocarcinomas, including gastric, colorectal, and pancreatic adenocarcinoma. High levels of CDH17 have been linked to metastatic disease and poor prognoses in patients with these malignancies, fueling interest in the protein as a target for diagnostics and therapeutics. Herein, we report the synthesis, in vitro validation, and in vivo evaluation of a CDH17-targeted 89 Zr-labeled immunoPET probe.

Methods

The CDH17-targeting mAb D2101 was modified with an isothiocyanate-bearing derivative of desferrioxamine (DFO) to produce a chelator-bearing immunoconjugate — DFO-D2101 — and flow cytometry and surface plasmon resonance (SPR) were used to interrogate its antigen-binding properties. The immunoconjugate was then radiolabeled with zirconium-89 ( t 1/2 ~ 3.3 days), and the serum stability and immunoreactive fraction of [ 89 Zr]Zr-DFO-D2101 were determined. Finally, [ 89 Zr]Zr-DFO-D2101’s performance was evaluated in a trio of murine models of pancreatic ductal adenocarcinoma (PDAC): subcutaneous, orthotopic, and patient-derived xenografts (PDX). PET images were acquired over the course of 5 days, and terminal biodistribution data were collected after the final imaging time point.

Results

DFO-D2101 was produced with a degree of labeling of ~ 1.1 DFO/mAb. Flow cytometry with CDH17-expressing AsPC-1 cells demonstrated that the immunoconjugate binds to its target in a manner similar to its parent mAb, while SPR with recombinant CDH17 revealed that D2101 and DFO-D2101 exhibit nearly identical K D values: 8.2 × 10 −9 and 6.7 × 10 −9 M, respectively. [ 89 Zr]Zr-DFO-D2101 was produced with a specific activity of 185 MBq/mg (5.0 mCi/mg), remained >80% stable in human serum over the course of 5 days, and boasted an immunoreactive fraction of >0.85. In all three murine models of PDAC, the radioimmunoconjugate yielded high contrast images, with high activity concentrations in tumor tissue and low uptake in non-target organs. Tumoral activity concentrations reached as high as >60 %ID/g in two of the cohorts bearing PDXs.

Conclusion

Taken together, these data underscore that [ 89 Zr]Zr-DFO-D2101 is a highly promising probe for the non-invasive visualization of CDH17 expression in PDAC. We contend that this radioimmunoconjugate could have a significant impact on the clinical management of patients with both PDAC and gastrointestinal adenocarcinoma, most likely as a theranostic imaging tool in support of CDH17-targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ZirconiumCadherinsRadioisotopesAnimalsHumansMiceCell Line, TumorPancreatic NeoplasmsDeferoxamineAdenocarcinomaImmunoconjugatesAntibodies, MonoclonalTissue DistributionPositron-Emission Tomography

Stichwörter der Autor:innen

AdenocarcinomaCadherin-17Pancreatic ductal adenocarcinomaPositron emission tomographyRadioimmunoconjugateZirconium-89

Substanzen

ZirconiumCadherinsRadioisotopesZirconium-89CDH17 protein, humanDeferoxamineImmunoconjugatesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Chemistry, Hunter College of the City University of New York, 413 East 69th Street, New York, NY, 10021, USA.
  • Ph.D. Program in Biochemistry, The Graduate Center of the City University of New York, New York, NY, USA.
  • Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Chemistry, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Department of Biological Sciences, Hunter College of the City University of New York, New York, NY, USA.
  • Ph.D. Program in Biology (Molecular, Cellular, and Developmental Biology Sub-Program), The Graduate Center of the City University of New York, New York, NY, USA.

ORCID-Profile: Brian M Zeglis

Förderung

  • Foundation for the National Institutes of Health
  • NCI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Delaney, S., Keinänen, O., Lam, D., Wolfe, A. L., Hamakubo, T., & Zeglis, B. M. (2024). Cadherin-17 as a target for the immunoPET of adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06709-7

Vancouver

Delaney S, Keinänen O, Lam D, Wolfe AL, Hamakubo T, Zeglis BM. Cadherin-17 as a target for the immunoPET of adenocarcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06709-7

BibTeX
@article{Delaney2024,
  author = {Delaney, Samantha and Keinänen, Outi and Lam, Dennis and Wolfe, Andrew L and Hamakubo, Takao and Zeglis, Brian M},
  title = {Cadherin-17 as a target for the immunoPET of adenocarcinoma},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06709-7}
}
Kostenlos starten →